Shilpa Medicare Partners with Finland’s Orion to Market Recombinant Human Albumin in Europe
By Ankur Chandra | Updated at: May 31, 2025 07:30 PM IST
Shilpa Medicare Limited has announced that its wholly owned subsidiary company, Shilpa Biocare Private Limited has collaborated with a Finland based Orion Corporation to market its Recombinant Human Albumin, the leading Biopharmaceutical of Shilpa Medicare Limited in Europe.
Key Partnership Highlights
| Particulars | Details |
|---|---|
| Partner Entity | Orion Corporation, Finland |
| Nature of Agreement | Exclusive distribution, marketing, and sales of Recombinant Human Albumin in Europe |
| Contract Type | International, non-related party arrangement |
| Financial Terms | Includes confidential milestone payments for development and regulatory success |
| Product Scope | Recombinant Human Albumin – a key plasma protein used in therapy and biologics manufacturing |
| Technology Platform | Developed via non-human expression system for virus-free, scalable production |
Strategic Intent & Rationale
We are pleased that this collaboration brings Shilpa Medicare to a significant milestone of expanding its global biopharmaceutical presence. The recombinant a project to which has already devoted nearly eight years is underpinned by its own closed and dedicated, large-scale, fermentation facility. The non-human expression system also provides safety, scale, and virus-free manufacture to alleviate the issue of the safety of human albumin.
“This collaboration with Orion serves as an important milestone in providing patients in Europe access to our novel recombinant offering,” Madhav Bhutada, Managing Director of Shilpa Biocare, said. “It is a reflection of our development and manufacturing capabilities, which can provide high-quality biologics to the rest of the globe.”
About Shilpa Medicare
Shilpa Medicare Ltd is a pharmaceutical and biotechnology company headquartered in Raichur, India, specializing in generics and biosimilars. It is known for its affordable and innovative healthcare offerings globally.
Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. The content is based on highly reliable resources. Still if there is any error it is deeply regretted. Write to us for getting any error corrected.
REF: https://nsearchives.nseindia.com/corporate/SHILPAMED_23052025150225_SEintimation23may2025.pdf
